Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

Steve N. Caritis, Shringi Sharma, Raman Venkataramanan, Gary Hankins, Menachem Miodovnik, Mary F. Hebert, Jason G. Umans, Thomas Benedetti, Donald Mattison, Anne Zajicek, Dawn Fischer, Aimee Jackson

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

Original languageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
Volume207
Issue number5
DOIs
StatePublished - Nov 2012

Fingerprint

17-alpha-Hydroxyprogesterone
Mothers
Pharmacology
Pregnancy
Injections
Pharmacokinetics
Half-Life
Body Mass Index
Fetal Blood
17-alpha-hydroxy-progesterone caproate
Pharmaceutical Preparations

Keywords

  • cord blood
  • pharmacokinetics
  • placenta
  • preterm birth

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Caritis, S. N., Sharma, S., Venkataramanan, R., Hankins, G., Miodovnik, M., Hebert, M. F., ... Jackson, A. (2012). Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. American Journal of Obstetrics and Gynecology, 207(5). https://doi.org/10.1016/j.ajog.2012.08.015

Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. / Caritis, Steve N.; Sharma, Shringi; Venkataramanan, Raman; Hankins, Gary; Miodovnik, Menachem; Hebert, Mary F.; Umans, Jason G.; Benedetti, Thomas; Mattison, Donald; Zajicek, Anne; Fischer, Dawn; Jackson, Aimee.

In: American Journal of Obstetrics and Gynecology, Vol. 207, No. 5, 11.2012.

Research output: Contribution to journalArticle

Caritis, SN, Sharma, S, Venkataramanan, R, Hankins, G, Miodovnik, M, Hebert, MF, Umans, JG, Benedetti, T, Mattison, D, Zajicek, A, Fischer, D & Jackson, A 2012, 'Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation', American Journal of Obstetrics and Gynecology, vol. 207, no. 5. https://doi.org/10.1016/j.ajog.2012.08.015
Caritis, Steve N. ; Sharma, Shringi ; Venkataramanan, Raman ; Hankins, Gary ; Miodovnik, Menachem ; Hebert, Mary F. ; Umans, Jason G. ; Benedetti, Thomas ; Mattison, Donald ; Zajicek, Anne ; Fischer, Dawn ; Jackson, Aimee. / Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. In: American Journal of Obstetrics and Gynecology. 2012 ; Vol. 207, No. 5.
@article{ab07c42737fc4548bb0f90c42c104229,
title = "Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation",
abstract = "Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.",
keywords = "cord blood, pharmacokinetics, placenta, preterm birth",
author = "Caritis, {Steve N.} and Shringi Sharma and Raman Venkataramanan and Gary Hankins and Menachem Miodovnik and Hebert, {Mary F.} and Umans, {Jason G.} and Thomas Benedetti and Donald Mattison and Anne Zajicek and Dawn Fischer and Aimee Jackson",
year = "2012",
month = "11",
doi = "10.1016/j.ajog.2012.08.015",
language = "English (US)",
volume = "207",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

AU - Caritis, Steve N.

AU - Sharma, Shringi

AU - Venkataramanan, Raman

AU - Hankins, Gary

AU - Miodovnik, Menachem

AU - Hebert, Mary F.

AU - Umans, Jason G.

AU - Benedetti, Thomas

AU - Mattison, Donald

AU - Zajicek, Anne

AU - Fischer, Dawn

AU - Jackson, Aimee

PY - 2012/11

Y1 - 2012/11

N2 - Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

AB - Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

KW - cord blood

KW - pharmacokinetics

KW - placenta

KW - preterm birth

UR - http://www.scopus.com/inward/record.url?scp=84868156082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868156082&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2012.08.015

DO - 10.1016/j.ajog.2012.08.015

M3 - Article

C2 - 22967833

AN - SCOPUS:84868156082

VL - 207

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 5

ER -